Zhitong Finance App News, Keji Pharmaceutical-B (02171.HK) issued an announcement. Preliminary results of clinical trials (CT041-CG4010, NCT06857786) conducted in China for claudin 18.2 positive gastro/esophagastric junction cancer patients after radical treatment (,) were conducted in China on October 25, 2026 (Sunday) CT041 The poster will be presented at the 2026 European Society of Medical Oncology (ESMO) Annual Meeting at 12:00-12:45 Central European Daylight Time (CEST).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.